Olfen Depocaps (Diclofenac Sodium)

Diclofenac sodium blocks the cyclo‑oxygenase enzymes COX‑1 and COX‑2, which are essential for producing prostaglandins. Prostaglandins promote inflammation, pain, and fever, so their reduction leads to decreased swelling, lower pain signals, and reduced fever, providing therapeutic relief in inflammatory disorders.

The specific dose of Olfen Depocaps is determined by the prescribing healthcare professional based on the patient’s condition, severity, age, renal and hepatic function, and other individual factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Diclofenac is generally avoided in the third trimester of pregnancy because of potential fetal cardiovascular effects. Use during earlier pregnancy or while breastfeeding should only occur if the prescriber judges that the benefit outweighs the risk. Women who are pregnant or nursing should discuss alternatives with their doctor.

To request Olfen Depocaps, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Olfen Depocaps (diclofenac) offers potent anti‑inflammatory and analgesic effects comparable to ibuprofen or naproxen, but it may have a higher risk of gastrointestinal and cardiovascular adverse events at equivalent doses. Choice of NSAID depends on the patient’s risk profile, required potency, and physician preference.

Olfen Depocaps should be stored at ambient temperature, preferably below 25 °C. Keep the capsules in their original container, protect them from moisture, heat and direct sunlight, and ensure the packaging remains tightly closed until use.

Olfen Depocaps is taken orally with a full glass of water. It may be taken with or without food, although taking it with food can reduce gastrointestinal discomfort. The exact timing and frequency are set by the prescribing clinician.

Serious risks include gastrointestinal bleeding or perforation, severe liver injury, acute kidney failure, and increased risk of cardiovascular events such as heart attack or stroke. Patients should be monitored for signs of these conditions and seek immediate medical attention if they occur.

Olfen Depocaps is contraindicated in individuals with known hypersensitivity to diclofenac or other NSAIDs, those with active gastrointestinal ulceration or bleeding, severe heart failure, and patients in the third trimester of pregnancy. It should also be avoided in patients with significant renal or hepatic impairment unless specifically directed by a physician.